The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals Inc.’s Trikafta to treat cystic fibrosis in children aged 6 to 11 years old, making the cocktail therapy the first approved treatment for CF in that age group.

The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.

AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.

Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.

BioSpace reviews some of the more interesting scientific studies recently published, including a Phase II clinical trial out of Hong Kong that found a three drug-antiviral cocktail significantly decreased median time to a negative SARS-CoV-2 test compared to controls.

A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.

A cheaper HIV prevention pill is going on sale in the United States, but experts say the price drop will not help as many people if doctors instead prescribe a newer, more expensive brand-name drug.

Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.